Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study

Habel, Laurel A.; Quesenberry, Charles P.; Jacobs, Marlena K.; Greenberg, David H.; Fehrenbacher, Louis; Alexander, C.; Baker, Joffre B.; Watson, Drew; Hackett, James; Shak, Steven

doi:10.1200/jco.2005.23.16_suppl.603

Cited by 12 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a multivariate analysis, the recurrence score predicted relapse and overall survival independently of age and tumor size. Similar results were observed in a community-based patient population in a separate study [16]. A recent report examined the value of the recurrence score for predicting benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy in 651 patients with ER-positive, node-negative breast cancer included in the NSABP B20 randomized study [17].…”

Section: Oncotype Dx™ and Other Prediction Scoressupporting

confidence: 57%

Molecular Classification of Breast Cancer: Limitations and Potential

Pusztai¹,

Mazouni²,

et al. 2006

View full text Add to dashboard Cite

Reverse transcription polymerase chain reaction and DNA microarrays are increasingly used in the clinic and in clinical research as prognostic or predictive tests. Results from these tests led to novel risk stratification methods and to new molecular classification of breast cancer. Some of these tools already complement existing diagnostic tests and can aid medical decision making in some situations. Better understanding of the molecular classes of breast cancer, independent of their prognostic and predictive values, may also lead to new biological insights and eventually to better therapies that are directed toward particular molecular subsets. However, there is substantially less experience with these emerging technologies than with the more established methods, the accuracy of which is often overestimated. This review discusses some of the limitations and strengths of current gene expression-based molecular classification of breast cancer. To provide context for this discussion, we also briefly examine the performance of estrogen receptor immunohistochemistry, which represents an essential part of the routine diagnostic workup for all breast cancer patients.

show abstract

Section: Oncotype Dx™ and Other Prediction Scoressupporting

confidence: 57%

Molecular Classification of Breast Cancer: Limitations and Potential

Pusztai¹,

Mazouni²,

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The results showed that 7% of low-risk patients (RS Ͻ18) relapsed, whereas 31% of high-risk patients (RS Ͼ31) relapsed. Subsequent studies have shown that the RS is independently associated with sensitivity to chemotherapy [29,30] and mortality [31].…”

Section: The Oncotype Dx™ Recurrence Score™mentioning

confidence: 99%

Current Status of Prognostic Profiling in Breast Cancer

Pusztai

2008

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Assess emerging data on the use of genetic groupings of breast cancer as predictive factors, and examine the efficacy of different therapies aimed at optimizing outcomes of patients within these groups.2. Examine the clinical value of molecular diagnostic tests being developed to classify breast tumors, and discuss the challenges involved in validating and interpreting the results of these tests. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT

show abstract

“…Since the Recurrence Score was validated in a relatively homogeneous patient population (LNN, ER+, tamoxifen-treated), it is not clear if its ability to predict distant recurrence is related to the natural history of the disease, to the tumor's responsiveness to tamoxifen, or to both. However, subsequent studies suggest that the Recurrence Score is independently associated with breast cancer mortality [50], chemotherapy sensitivity and tamoxifen resistance (discussed further below) [51,52] As mentioned above, the Rotterdam 76-gene signature was specifically devloped to address the clinical question of how to identify those patients with lymph node negative breast cancer that would benefit from adjuvant systemic therapy, regardless of hormone receptor status, since the majority of these patients are cured with locoregional treatment [53]. Two hundred eighty-six patients with LNN breast cancer that had not received adjuvant therapy were divided into ER− and ER+ groups and subjected to gene expression profiling.…”

Section: Prognostic Profilesmentioning

confidence: 95%

Molecular profiling in breast cancer

Morris

Carey

2007

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Molecular profiling has provided biological evidence for the heterogeneity of breast cancer through the identification of intrinsic subtypes like Luminal A, Luminal B, HER2+/ER- and basal-like. It has also led to the development of clinically applicable gene expression-based prognostic panels like the Mammaprint and Oncotype Dx. The increasingly sophisticated understanding allowed by this and similar technology promises future individualized therapy.

show abstract

Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study

Cited by 12 publications

References 0 publications

Molecular Classification of Breast Cancer: Limitations and Potential

Molecular Classification of Breast Cancer: Limitations and Potential

Current Status of Prognostic Profiling in Breast Cancer

Molecular profiling in breast cancer

Contact Info

Product

Resources

About